SBC 014
Alternative Names: AES-014; AVI-014; SBC-014Latest Information Update: 02 Oct 2021
At a glance
- Originator Synageva BioPharma
- Class Granulocyte colony-stimulating factors; Proteins; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Neutropenia
Most Recent Events
- 04 Nov 2010 Synageva BioPharma receives 12 grants under the US Government's Qualifying Therapeutic Discovery Project Programme
- 30 Sep 2008 SBC 014 is available for licensing and/or co-development in the USA (http://www.synageva.com)
- 30 Nov 2005 This programme is still in active development - (BIO-Europe-2005)